Stock Watch: CSL Takes Knocks Punching Above Its Weight
Executive Summary
CSL’s evolution from plasma fractioneer to biotech has reached the extent of an approved gene therapy just as gene therapy commercialization faces challenges. Meanwhile, in the post-pandemic inflationary environment, CSL’s margins in its biggest blood products division are impacted by increased donor fees and higher labor costs.
You may also be interested in...
Stock Watch: Lilly And Novo Provide An Earnings Season Crescendo
The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.
England: CSL Undeterred By Draft NICE Rejection Of Its £2.6m Hemophilia B Gene Therapy
CSL Behring said it remains confident that a market access agreement for its hemophilia B gene therapy Hemgenix can be reached after England’s HTA body NICE rejected the product because of uncertainties over its long-term benefit and cost-effectiveness.
Stock Watch: Q2 Earnings Shelter Novartis From Recent Storms
Novartis’s positive start to second-quarter earnings season also made more acute the potential impact of the recent invalidation of the patent on its biggest product.